We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Calliditas Therapeutics Ab | LSE:0A5R | London | Ordinary Share | SE0010441584 | CALLIDITAS THERAPEUTICS ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 54 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 805.74M | -412.27M | -6.9196 | -1.09 | 449.83M |
STOCKHOLM, May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 pm CET/8:30 am ET. Calliditas will also host 1x1 meetings during the conference. Details for the presentation are as follows:
Jefferies Virtual Healthcare Conference
Date: Tuesday, June 1, 2021
Time: 2:30 pm CET / 8:30 am ET
Registration Link: https://wsw.com/webcast/jeff174/register.aspx?conf=jeff174&page=calt&mmid=3325730&refer=meetmax&firstname=&lastname=
The webcast will be archived for a period of 30 days following the conclusion of the event.
For further information, please contact:
Marie Galay, IR Manager, Calliditas
Tel.: +44 79 55 12 98 45
email: marie.galay@calliditas.com
The information was sent for publication, through the agency of the contact persons set out above, on May 28, 2021 at 12:00 p.m. CET.
About Calliditas
Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas successfully reported top line data of its global Phase 3 study in IgAN in November of 2020 and, if approved, aims to commercialize Nefecon in the United States on its own and partner elsewhere. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/calliditas-therapeutics-to-present-at-jefferies-virtual-healthcare-conference,c3356146
The following files are available for download:
https://mb.cision.com/Main/16574/3356146/1424287.pdf | Jefferies Conference Press Release - En |
View original content:http://www.prnewswire.com/news-releases/calliditas-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-301301624.html
SOURCE Calliditas Therapeutics
Copyright 2021 PR Newswire
1 Year Calliditas Therapeutics Ab Chart |
1 Month Calliditas Therapeutics Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions